Focus V (Anlotinib)

About Anlotinib 

Anlotinib is a orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. 

• Anlotinib sold as brand name 福可维® (Focus V) in china.

Anlotinib is used to treat advanced soft tissue sarcomas, including alveolar soft tissue sarcoma and clear cell sarcoma, after at least one chemotherapy regimen. Anlotinib is a targeted drug that can be used as a maintenance treatment after chemotherapy.

Dosage

The recommended dose of anlotinib hydrochloride is 12 mg once a day, orally before breakfast.
Take the medicine continuously for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) is a course of treatment.
Until the disease progresses or intolerable adverse reactions occur.
If a dose is missed during medication, confirm that the time from the next dose is less than 12 hours, then no more supplementary doses will be taken.

Adverse reactions should be closely monitored during the use of this product, and adjustments should be made according to the adverse reactions so that patients can tolerate the treatment. Adverse reactions caused by this product can be treated by symptomatic treatment, suspension of medication and/or adjustment of dosage. According to the degree of adverse reactions, it is recommended to adjust the dose under the guidance of a physician:
① The first dose adjustment: 10 mg, once a day, for 2 consecutive weeks, and stop for 1 week;
② The second dose adjustment: 8 mg, once a day, for 2 consecutive weeks, and stop for 1 week.
If the 8mg dose is still intolerable, the drug should be permanently discontinued.